Hormonal
Incretin-based therapies (liraglutide, semaglutide, tirzepatide) produce significant body weight reduction (≥5% in majority of patients) and reduce the 10-year relative risk of type 2 diabetes development by 60-69% in individuals with obesity.
If you have obesity or overweight with related health issues, incretin-based medications (like semaglutide or tirzepatide) are highly effective for significant weight loss and preventing type 2 diabetes. They work by mimicking hormones that regulate appetite and are taken weekly (or daily for liraglutide) alongside lifestyle changes. These are not quick fixes but long-term treatments requiring continuous use to maintain results.
Incretin-based therapies have been associated with a body weight (BW) reduction of ≥5% in at least half of patients in most randomized controlled trials (RCT) and real-world studies (RWS). Semaglutide and tirzepatide have also displayed a mean 60–69% 10-years relative risk reduction of T2D development.
Why this rating
Supported by multiple Phase 3 RCTs (SCALE, STEP, SURMOUNT) and real-world studies.
Source
Incretin-based therapies for the treatment of obesity-related diseases
Irene Caruso et al. · npj Metabolic Health and Disease · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →